Bridgefront Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Bridgefront Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,058	Closed	-$1.08M	–	787
2025 Q2	$1.08M	Buy	2,058 +1,190	+137%	+$664K	0.29%	80
2025 Q1	$551K	Buy	+868	New	+$597K	0.16%	228
2024 Q4	–	Sell	-391	Closed	-$411K	–	751
2024 Q3	$411K	Buy	+391	New	+$435K	0.16%	239
2023 Q3	–	Sell	-539	Closed	-$387K	–	570
2023 Q2	$387K	Buy	+539	New	+$416K	0.21%	186
2021 Q3	–	Sell	-1,710	Closed	-$955K	–	609
2021 Q2	$955K	Sell	1,710 -110	-6%	-$55.7K	0.36%	56
2021 Q1	$861K	Buy	1,820 +327	+22%	+$159K	0.27%	79
2020 Q4	$721K	Buy	+1,493	New	+$806K	0.25%	116

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bridgefront Capital's REGN Position: Q3 2025 in Review

Bridgefront Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 2,058 shares — an estimated $1.08M sold.

Bridgefront Capital first reported a position in REGN in Q4 2020 and held it in 7 quarters. The position peaked at $1.08M in Q2 2025. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Bridgefront Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Bridgefront Capital sold 2,058 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $1.08M.
Bridgefront Capital first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Bridgefront Capital's Regeneron Pharmaceuticals position peaked at $1.08M in Q2 2025.
1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Bridgefront Capital's 13F filing for Q3 2025, filed 14 Nov 2025.